Serum bradykinin levels as a diagnostic marker in cervical cancer with a potential mechanism to promote VEGF expression via BDKRB2

Zhou,Ying; Wang,Wei; Wei,Rui; Jiang,Guiying; Li,Fei; Chen,Xi; Wang,Xueqian; Long,Sixiang; Ma,Ding; Xi,Ling

doi:10.3892/ijo.2019.4792

Serum bradykinin levels as a diagnostic marker in cervical cancer with a potential mechanism to promote VEGF expression via BDKRB2

Authors:
- Ying Zhou
- Wei Wang
- Rui Wei
- Guiying Jiang
- Fei Li
- Xi Chen
- Xueqian Wang
- Sixiang Long
- Ding Ma
- Ling Xi
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: May 2, 2019 https://doi.org/10.3892/ijo.2019.4792
Pages: 131-141
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bradykinin (BK) is one of the kinin peptides and preferentially binds to bradykinin B2 receptor (BDKRB2). A recent study indicated that BK played an important role in the occurrence and progression of cancer. In this study, we evaluated the serum BK levels in 130 cervical cancer (CC) cases (including 65 cases with pre‑ and post‑surgery paired samples, another 65 cases with only pre‑surgery samples), 35 cervical intraepithelial neoplasia (CIN) cases (pre‑ and post‑surgery paired) and 35 control cases. We found that BK was overexpressed in patients with CC compared to patients with CIN and the control group. When combined with squamous cell carcinoma‑related antigen (SCCA), the diagnostic efficacy of BK was prominently enhanced. Moreover, we detected the expression level of the BK receptor BDKRB2 in CC, CIN and normal cervical tissues and observed a higher expression in the CC and CIN tissues than in the normal cervix. We then explored the possible mechanisms of action of BK in promoting the progression of CC. When BK was added to the cell culture medium, human umbilical vein endothelial cell (HUVEC) angiogenesis increased and vascular endothelial growth factor (VEGF) expression in CC cell lines was also elevated. The BK antagonist, HOE140, exerted an opposite effect. The knockdown or the overexpression of BDKRB2 in CC cell lines further confirmed its oncogenic role in angiogenesis. Taken together, the findings of this study suggest that BK may be a diagnostic biomarker for CC and may notably improve the diagnostic efficacy when combined with SCCA. BK promotes the progression of CC by upregulating the expression of VEGF via BDKRB2 and subsequently facilitating angiogenesis.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dorigo O, et al: Cervical Cancer, Version 2.2015. J Natl Compr Canc Netw. 13:395–404; quiz 404. 2015. View Article : Google Scholar : PubMed/NCBI
4	Di J, Rutherford S and Chu C: Review of the cervical cancer burden and population-based cervical cancer screening in China. Asian Pac J Cancer Prev. 16:7401–7407. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ueda Y, Enomoto T and Kimura T, Miyatake T, Yoshino K, Fujita M and Kimura T: Serum biomarkers for early detection of gynecologic cancers. Cancers (Basel). 2:1312–1327. 2010. View Article : Google Scholar
6	Pectasides D, Economides N, Bourazanis J, Pozadzizou P, Gogou L, Koutsiouba P and Athanassiou A: Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer. Am J Clin Oncol. 17:307–312. 1994. View Article : Google Scholar : PubMed/NCBI
7	Nam JH, Chang KC, Chambers JT, Schwartz PE and Cole LA: Urinary gonadotropin fragment, a new tumor marker. III. Use in cervical and vulvar cancers. Gynecol Oncol. 38:66–70. 1990. View Article : Google Scholar : PubMed/NCBI
8	da Costa PL, Sirois P, Tannock IF and Chammas R: The role of kinin receptors in cancer and therapeutic opportunities. Cancer Lett. 345:27–38. 2014. View Article : Google Scholar
9	Bhoola KD, Figueroa CD and Worthy K: Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev. 44:1–80. 1992.PubMed/NCBI
10	Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, BrogiE Boyd J, et al: Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 116:271–284. 2006. View Article : Google Scholar : PubMed/NCBI
11	van Winden AW, van den Broek I, Gast MC, Engwegen JY, Sparidans RW, van Dulken EJ, Depla AC, Cats A, Schellens JH, Peeters PH, et al: Serum degradome markers for the detection of breast cancer. J Proteome Res. 9:3781–3788. 2010. View Article : Google Scholar : PubMed/NCBI
12	Ishihara K, Kamata M, Hayashi I, Yamashina S and Majima M: Roles of bradykinin in vascular permeability and angiogenesis in solid tumor. Int Immunopharmacol. 2:499–509. 2002. View Article : Google Scholar : PubMed/NCBI
13	Ikeda Y, Hayashi I, Kamoshita E, Yamazaki A, Endo H, Ishihara K, Yamashina S, Tsutsumi Y, Matsubara H and Majima M: Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res. 64:5178–5185. 2004. View Article : Google Scholar : PubMed/NCBI
14	Yu HS, Wang SW, Chang AC, Tai HC, Yeh HI, Lin YM and Tang CH: Bradykinin promotes vascular endothelial growth factor expression and increases angiogenesis in human prostate cancer cells. Biochem Pharmacol. 87:243–253. 2014. View Article : Google Scholar
15	Chen Y, Yu Y, Sun S, Wang Z, Liu P, Liu S and Jiang J: Bradykinin promotes migration and invasion of hepatocellular carcinoma cells through TRPM7 and MMP2. Exp Cell Res. 349:68–76. 2016. View Article : Google Scholar : PubMed/NCBI
16	Andoh T, Akira A, Saiki I and Kuraishi Y: Bradykinin increases the secretion and expression of endothelin-1 through kinin B2 receptors in melanoma cells. Peptides. 31:238–241. 2010. View Article : Google Scholar
17	Wang G, Sun J, Liu G, Fu Y and Zhang X: Bradykinin promotes cell proliferation, migration, invasion, and tumor growth of gastric cancer through ERK signaling pathway. J Cell Biochem. 118:4444–4453. 2017. View Article : Google Scholar : PubMed/NCBI
18	Bechtold V, Beard P and Raj K: Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA. J Virol. 77:2021–2028. 2003. View Article : Google Scholar : PubMed/NCBI
19	Hu Z, Ding W, Zhu D, Yu L, Jiang X, Wang X, Zhang C, Wang L, Ji T, Liu D, et al: TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. J Clin Invest. 125:425–436. 2015. View Article : Google Scholar :
20	de Bruijn HW, Duk JM, van der Zee AG, Pras E, Willemse PH, Boonstra H, Hollema H, Mourits MJ, de Vries EG and Aalders JG: The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix. Tumour Biol. 19:505–516. 1998. View Article : Google Scholar : PubMed/NCBI
21	Bolger BS, Dabbas M, Lopes A and Monaghan JM: Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma. Gynecol Oncol. 65:309–313. 1997. View Article : Google Scholar : PubMed/NCBI
22	Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol. 3:65–71. 1992.PubMed/NCBI
23	McMahon G: VEGF receptor signaling in tumor angiogenesis. Oncologist. 5(Suppl 1): 3–10. 2000. View Article : Google Scholar : PubMed/NCBI
24	Amini A, Masoumi Moghaddam S, Morris DL and Pourgholami MH: The critical role of vascular endothelial growth factor in tumor angiogenesis. Curr Cancer Drug Targets. 12:23–43. 2012. View Article : Google Scholar
25	Ulrich H, Ratajczak MZ, Schneider G, Adinolfi E, Orioli E, Ferrazoli EG, Glaser T, Corrêa-Velloso J, Martins PCM, Coutinho F, et al: Kinin and purine signaling contributes to neuroblastoma metastasis. Front Pharmacol. 9:5002018. View Article : Google Scholar : PubMed/NCBI
26	Figueroa CD, Ehrenfeld P and Bhoola KD: Kinin receptors as targets for cancer therapy. Expert Opin Ther Targets. 16:299–312. 2012. View Article : Google Scholar : PubMed/NCBI
27	Wu J, Akaike T, Hayashida K, Miyamoto Y, Nakagawa T, Miyakawa K, Müller-Esterl W and Maeda H: Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer. 98:29–35. 2002. View Article : Google Scholar : PubMed/NCBI
28	Dubuc C, Savard M, Bovenzi V, Lessard A, Fortier A, Côté J, Neugebauer W, Rizzolio F, Geha S, Giordano A, et al: Targeting intracellular B2 receptors using novel cell-penetrating antagonists to arrest growth and induce apoptosis in human triple-negative breast cancer. Oncotarget. 9:9885–9906. 2018. View Article : Google Scholar : PubMed/NCBI
29	Chan D, Gera L, Stewart J, Helfrich B, Verella-Garcia M, Johnson G, Baron A, Yang J, Puck T and Bunn P Jr: Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a 'biased agonist' mechanism. Proc Natl Acad Sci USA. 99:4608–4613. 2002. View Article : Google Scholar
30	Chan DC, Gera L, Stewart JM, Helfrich B, Zhao TL, Feng WY, Chan KK, Covey JM and Bunn PA Jr: Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res. 8:1280–1287. 2002.PubMed/NCBI
31	Lin KS, Pan J, Amouroux G, Turashvili G, Mesak F, Hundal-Jabal N, Pourghiasian M, Lau J, Jenni S, Aparicio S, et al: In vivo radioimaging of bradykinin receptor B1, a widely overex-pressed molecule in human cancer. Cancer Res. 75:387–393. 2015. View Article : Google Scholar
32	Kuo HT, Pan J, Lau J, Zhang C, Zeisler J, Colpo N, Bénard F and Lin KS: Radiolabeled R954 derivatives for imaging bradykinin B1 receptor expression with positron emission tomography. Mol Pharm. 14:821–829. 2017. View Article : Google Scholar : PubMed/NCBI
33	Amouroux G, Zhang Z, Pan J, Jenni S, Zhang C, Hundal-Jabal N, Colpo N, Zeisler J, Lin KS and Bénard F: Synthesis and evaluation of a 68Ga-labeled bradykinin B1 receptor agonist for imaging with positron emission tomography. Bioorg Med Chem. 25:690–696. 2017. View Article : Google Scholar
34	Dubuc C, Savard M, Bovenzi V, Lessard A, Côté J, Neugebauer W, Geha S, Chemtob S and Gobeil F Jr: Antitumor activity of cell-penetrant kinin B1 receptor antagonists in human triple-negative breast cancer cells. J Cell Physiol. 234:2851–2865. 2019. View Article : Google Scholar
35	Kontos CK, Mavridis K, Talieri M and Scorilas A: Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: Mechanistic and clinical aspects. Thromb Haemost. 110:450–457. 2013. View Article : Google Scholar : PubMed/NCBI
36	Hong SK: Kallikreins as biomarkers for prostate cancer. BioMed Res Int. 2014:5263412014. View Article : Google Scholar : PubMed/NCBI